Abstract
The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated Cl- channel whose major function is to facilitate epithelial fluid secretion. Loss-of-function mutations in CFTR cause the genetic disease cystic fibrosis. CFTR is required for transepithelial fluid transport in certain secretory diarrheas, such as cholera, and for cyst expansion in autosomal dominant polycystic kidney disease. High-throughput screening has yielded CFTR inhibitors of the thiazolidinone, glycine hydrazide and quinoxalinedione chemical classes. The glycine hydrazides target the extracellular CFTR pore, whereas the thiazolidinones and quinoxalinediones act at the cytoplasmic surface. These inhibitors have been widely used in cystic fibrosis research to study CFTR function at the cell and organ levels. The most potent CFTR inhibitor has IC50 of approximately 4 nM. Studies in animal models support the development of CFTR inhibitors for antisecretory therapy of enterotoxin-mediated diarrheas and polycystic kidney disease.
Keywords: Chloride channels, cystic fibrosis, diarrhea, polycystic kidney disease, drug discovery.
Current Pharmaceutical Design
Title:CFTR Inhibitors
Volume: 19 Issue: 19
Author(s): Alan S. Verkman, David Synder, Lukmanee Tradtrantip, Jay R. Thiagarajah and Marc O. Anderson
Affiliation:
Keywords: Chloride channels, cystic fibrosis, diarrhea, polycystic kidney disease, drug discovery.
Abstract: The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated Cl- channel whose major function is to facilitate epithelial fluid secretion. Loss-of-function mutations in CFTR cause the genetic disease cystic fibrosis. CFTR is required for transepithelial fluid transport in certain secretory diarrheas, such as cholera, and for cyst expansion in autosomal dominant polycystic kidney disease. High-throughput screening has yielded CFTR inhibitors of the thiazolidinone, glycine hydrazide and quinoxalinedione chemical classes. The glycine hydrazides target the extracellular CFTR pore, whereas the thiazolidinones and quinoxalinediones act at the cytoplasmic surface. These inhibitors have been widely used in cystic fibrosis research to study CFTR function at the cell and organ levels. The most potent CFTR inhibitor has IC50 of approximately 4 nM. Studies in animal models support the development of CFTR inhibitors for antisecretory therapy of enterotoxin-mediated diarrheas and polycystic kidney disease.
Export Options
About this article
Cite this article as:
Verkman Alan S., Synder David, Tradtrantip Lukmanee, Thiagarajah Jay R. and Anderson Marc O., CFTR Inhibitors, Current Pharmaceutical Design 2013; 19 (19) . https://dx.doi.org/10.2174/13816128113199990321
DOI https://dx.doi.org/10.2174/13816128113199990321 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Delivery of Growth Factors by HSV-Mediated Gene Transfer for Peripheral Neuropathy
Current Gene Therapy X-Ray Versus Magnetic Resonance Imaging in Diabetic Foot Osteomyelitis: A Clinical Comparison
Current Diabetes Reviews Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy
CNS & Neurological Disorders - Drug Targets Comparative Studies of the Chromogranin A-Derived Neuropeptide WE-14
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Na+/Ca2+ Exchange Inhibitors: A New Class of Calcium Regulators
Cardiovascular & Hematological Disorders-Drug Targets MicroRNAs and Physical Activity
MicroRNA Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Disorder in Milk Proteins: α -Lactalbumin. Part A. Structural Properties and Conformational Behavior
Current Protein & Peptide Science A Review of Obesity and Body Fat Distribution and Its Relationship to Cardio-Metabolic Risk in Men and Women of Chinese Origin
Cardiovascular & Hematological Disorders-Drug Targets Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Obstructive Sleep Apnea and Type 2 Diabetes: Dual Interaction
Current Respiratory Medicine Reviews Pathophysiology of Hypertension During Preeclampsia: Role of Inflammatory Cytokines
Current Hypertension Reviews Targeting PPAR Isoforms Following CNS Injury
Current Drug Targets Heat Shock Proteins Protect Against Ischemia and Inflammation Through Multiple Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Protection by Natural Honey Against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Insoluble Solids in Brazilian and Floridian Acai (Euterpe oleraceae Mart.)
The Natural Products Journal The Role of the Status of Selected Micronutrients in Shaping the Immune Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Transcriptional Regulation of Glucose Sensors in Pancreatic β Cells and Liver
Current Diabetes Reviews MR Imaging of Pancreatic Islets: Tracking Isolation, Transplantation and Function
Current Pharmaceutical Design